HomeCompareRHNMF vs MRK

RHNMF vs MRK: Dividend Comparison 2026

RHNMF yields 10526.32% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RHNMF wins by $91421458538285344.00M in total portfolio value
10 years
RHNMF
RHNMF
● Live price
10526.32%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$91421458538285344.00M
Annual income
$89,744,322,218,307,970,000,000.00
Full RHNMF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — RHNMF vs MRK

📍 RHNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHNMFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHNMF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHNMF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHNMF
Annual income on $10K today (after 15% tax)
$894,736.84/yr
After 10yr DRIP, annual income (after tax)
$76,282,673,885,561,770,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, RHNMF beats the other by $76,282,673,885,561,770,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHNMF + MRK for your $10,000?

RHNMF: 50%MRK: 50%
100% MRK50/50100% RHNMF
Portfolio after 10yr
$45710729269142672.00M
Annual income
$44,872,161,109,153,986,000,000.00/yr
Blended yield
98.17%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

RHNMF
No analyst data
Altman Z
-9.5
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHNMF buys
0
MRK buys
0
No recent congressional trades found for RHNMF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHNMFMRK
Forward yield10526.32%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$91421458538285344.00M$56.8K
Annual income after 10y$89,744,322,218,307,970,000,000.00$9,798.13
Total dividends collected$91309952364754128.00M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RHNMF vs MRK ($10,000, DRIP)

YearRHNMF PortfolioRHNMF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$1,063,332$1,052,631.58$11,206$366.19+$1.05MRHNMF
2$105,744,905$104,607,140.08$12,650$502.35+$105.73MRHNMF
3$9,835,430,757$9,722,283,708.79$14,407$694.19+$9835.42MRHNMF
4$855,644,041,989$845,120,131,078.84$16,585$967.82+$855644.03MRHNMF
5$69,627,827,846,009$68,712,288,721,080.95$19,342$1,363.89+$69627827.83MRHNMF
6$5,300,152,192,813,391$5,225,650,417,018,161.00$22,913$1,947.19+$5300152192.79MRHNMF
7$377,430,657,448,967,200$371,759,494,602,656,830.00$27,662$2,823.89+$377430657448.94MRHNMF
8$25,145,413,383,015,215,000$24,741,562,579,544,820,000.00$34,159$4,173.35+$25145413383015.18MRHNMF
9$1,567,417,121,474,185,500,000$1,540,511,529,154,359,300,000.00$43,337$6,308.80+$1567417121474185.50MRHNMF
10$91,421,458,538,285,340,000,000$89,744,322,218,307,970,000,000.00$56,776$9,798.13+$91421458538285344.00MRHNMF

RHNMF vs MRK: Complete Analysis 2026

RHNMFStock

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is headquartered in Cremorne, Australia.

Full RHNMF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this RHNMF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHNMF vs SCHDRHNMF vs JEPIRHNMF vs ORHNMF vs KORHNMF vs MAINRHNMF vs JNJRHNMF vs ABBVRHNMF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.